These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 33459260

  • 1. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
    Ludwig SV, F Cheng P, Mangana J, Braun R, Dummer R, Koelblinger P.
    Eur J Dermatol; 2020 Dec 01; 30(6):699-709. PubMed ID: 33459260
    [Abstract] [Full Text] [Related]

  • 2. Improved survival for stage IV melanoma from an unknown primary site.
    Lee CC, Faries MB, Wanek LA, Morton DL.
    J Clin Oncol; 2009 Jul 20; 27(21):3489-95. PubMed ID: 19451446
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
    Verver D, Grünhagen DJ, van Akkooi ACJ, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Tije AJT, Vreugdenhil G, Verhoef C, van der Veldt AAM.
    Cancer Immunol Immunother; 2021 Nov 20; 70(11):3123-3135. PubMed ID: 33774697
    [Abstract] [Full Text] [Related]

  • 4. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
    Lee CC, Faries MB, Wanek LA, Morton DL.
    J Clin Oncol; 2008 Feb 01; 26(4):535-41. PubMed ID: 18235114
    [Abstract] [Full Text] [Related]

  • 5. Melanoma of unknown primary origin: a population-based study in the Netherlands.
    de Waal AC, Aben KK, van Rossum MM, Kiemeney LA.
    Eur J Cancer; 2013 Feb 01; 49(3):676-83. PubMed ID: 23031553
    [Abstract] [Full Text] [Related]

  • 6. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
    van der Ploeg AP, Haydu LE, Spillane AJ, Scolyer RA, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Thompson JF.
    Ann Surg Oncol; 2014 Sep 01; 21(9):3108-16. PubMed ID: 24802907
    [Abstract] [Full Text] [Related]

  • 7. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.
    Utter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, Pavlick AC, Osman I.
    Oncology; 2017 Sep 01; 93(4):249-258. PubMed ID: 28746931
    [Abstract] [Full Text] [Related]

  • 8. Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary.
    Persa OD, Hassel JC, Steeb T, Erdmann M, Karimi B, Stege H, Klespe KC, Schatton K, Tomsitz D, Rübben A, Thiem A, Berking C, Biedermann T.
    J Immunother; 2017 Sep 01; 47(9):384-387. PubMed ID: 39206786
    [Abstract] [Full Text] [Related]

  • 9. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.
    Prens SP, van der Ploeg AP, van Akkooi AC, van Montfort CA, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C.
    Ann Surg Oncol; 2011 Dec 01; 18(13):3586-92. PubMed ID: 21611857
    [Abstract] [Full Text] [Related]

  • 10. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
    Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM.
    J Immunother Cancer; 2022 Jan 01; 10(1):. PubMed ID: 35074904
    [Abstract] [Full Text] [Related]

  • 11. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.
    Scott JF, Conic RZ, Thompson CL, Gerstenblith MR, Bordeaux JS.
    J Am Acad Dermatol; 2018 Aug 01; 79(2):258-265.e4. PubMed ID: 29580859
    [Abstract] [Full Text] [Related]

  • 12. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies.
    Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, Kim H, Oh BH, Roh MR, Nam KA, Chung KY.
    J Am Acad Dermatol; 2015 Jan 01; 72(1):59-70. PubMed ID: 25440435
    [Abstract] [Full Text] [Related]

  • 13. Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.
    Gullestad HP, Ryder T, Goscinski M.
    J Plast Surg Hand Surg; 2023 Jan 01; 57(1-6):109-114. PubMed ID: 34878354
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.
    Eur J Cancer; 2019 Jul 01; 116():207-215. PubMed ID: 31212163
    [Abstract] [Full Text] [Related]

  • 15. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 01; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 16. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE.
    Ann Surg Oncol; 2020 Apr 01; 27(4):1180-1188. PubMed ID: 31848819
    [Abstract] [Full Text] [Related]

  • 17. Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients.
    Crookes TR, Scolyer RA, Lo S, Drummond M, Spillane AJ.
    Ann Surg Oncol; 2017 May 01; 24(5):1378-1385. PubMed ID: 28130620
    [Abstract] [Full Text] [Related]

  • 18. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK.
    Lancet Oncol; 2016 Nov 01; 17(11):e481. PubMed ID: 27746107
    [No Abstract] [Full Text] [Related]

  • 19. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 20. Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.
    Del Fiore P, Rastrelli M, Dall'Olmo L, Cavallin F, Cappellesso R, Vecchiato A, Buja A, Spina R, Parisi A, Mazzarotto R, Ferrazzi B, Grego A, Rotondi A, Benna C, Tropea S, Russano F, Filoni A, Bassetto F, Tos APD, Alaibac M, Rossi CR, Pigozzo J, Sileni VC, Mocellin S.
    Front Oncol; 2021 Jun 01; 11():627527. PubMed ID: 33747946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.